Allergy Therapeutics has begin its G205 Phase II study to check the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy. It will be used to treat the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
Allergy Therapeutics has appointed Jeff Barton to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.
Allergy Therapeutics, a pharmaceutical company specialising in allergy vaccines, has announced positive results from preclinical research of its therapeutic peanut allergy vaccine, Polyvac Peanut.
European Patent Office OKs new patent for Allergy Therapeutics’ Microcrystalline Tyrosine tech
Allergy Therapeutics Acarovac Plus one year study published
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.